Prevalence and severity of asthmatic symptoms in Grenadian school children: the Grenada National Asthma Survey

Toxic effects of perinatal maternal exposure to nonylphenol on lung inflammation in male offspring rats

The incidence of asthma and its related allergic diseases has increased dramatically over the last decade. Asthma is a complex disease caused by genetic and environmental factors. Nonylphenol (NP), a typical endocrine disrupting chemical (EDC), is a major current focus in asthma research. Pregnant Sprague-Dawley rats (n = 8-10 per group) were given a consecutive daily dose of NP (25, 50, or 100 mg/kg/day) or an equivalent volume of vehicle by gavage from gestational day 7 until postnatal day (PND) 21. Exposure to 100 mg/kg NP increased the body mass of the offspring on PND 43. Perinatal exposure to NP in maternal rats led to a dose-dependent increase of NP level in the lung tissue of the offspring. The numbers of lymphocytes and neutrophils in bronchoalveolar lavage fluid were significantly higher in the 100 mg/kg NP group than those in the control. Histopathological examination of the lung showed that exposure to high dose NP resulted in a slightly thickened bronchiolar smooth muscles with inflammatory cell infiltration. In the cytoplasm of type II epithelial cells, osmiophilic lamellar bodies were observed, with emptied lamellar bodies. NP significantly increased the expressions of high mobility group box 1 protein (HMGB1) mRNA and nuclear factor κB (NF-κB) mRNA in the lung tissue of the offspring in a dose dependent manner. Similarly, the expressions of HMGB1, NF-κBp65 and estrogen receptor-β (ER-β) proteins increased with an increase of NP dose. NP content was positively correlated with the expressions of HMGB1 and NF-κB mRNA as well as HMGB1, NF-κBp65, and ER-β proteins in the lung tissue of offspring. Perinatal exposure to NP from the maternal rats might induce airway inflammation in the offspring, which may be due to NP-induced infiltration of inflammatory cells into the airway, and pathological alterations in airway structure as well as abnormal expression patterns of inflammation-related genes, proteins (including HMGB1 and NF-κB) and estrogen receptor β.

Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies

Genetic variants associated with asthma pathogenesis and altered response to drug therapy are discussed. Many studies implicate polymorphisms in genes encoding the enzymes responsible for leukotriene synthesis and intracellular signaling through activation of seven transmembrane domain receptors, such as the cysteinyl leukotriene 1 (CYSLTR1) and 2 (CYSLTR2) receptors. The leukotrienes are polyunsaturated lipoxygenated eicosatetraenoic acids that exhibit a wide range of pharmacological and physiological actions. Of the three enzymes involved in the formation of the leukotrienes, arachidonate 5 lipoxygenase 5 (ALOX5), leukotriene C4 synthase (LTC4S), and leukotriene hydrolase (LTA4H) are all polymorphic. These polymorphisms often result in variable production of the CysLTs (LTC4, LTD4, and LTE4) and LTB4. Variable number tandem repeat sequences located in the Sp1-binding motif within the promotor region of the ALOX5 gene are associated with leukotriene burden and bronchoconstriction independent of asthma risk. A 444A > C SNP polymorphism in the LTC4S gene, encoding an enzyme required for the formation of a glutathione adduct at the C-6 position of the arachidonic acid backbone, is associated with severe asthma and altered response to the CYSLTR1 receptor antagonist zafirlukast. Genetic variability in the CysLT pathway may contribute additively or synergistically to altered drug responses. The 601 A > G variant of the CYSLTR2 gene, encoding the Met201Val CYSLTR2 receptor variant, is associated with atopic asthma in the general European population, where it is present at a frequency of ∼2.6%. The variant was originally found in the founder population of Tristan da Cunha, a remote island in the South Atlantic, in which the prevalence of atopy is approximately 45% and the prevalence of asthma is 36%. In vitro work showed that the atopy-associated Met201Val variant was inactivating with respect to ligand binding, Ca²⁺ flux and inositol phosphate generation. In addition, the CYSLTR1 gene, located at Xq13-21.1, has been associated with atopic asthma. The activating Gly300Ser CYSLTR1 variant is discussed. In addition to genetic loci, risk for asthma may be influenced by environmental factors such as smoking. The contribution of CysLT pathway gene sequence variants to atopic asthma is discussed in the context of other genes and environmental influences known to influence asthma.